Community-acquired diarrhea is typically caused by consumption of contaminated food or water containing bacterial, viral, or parasitic gastrointestinal pathogens.
Since symptoms alone are not sufficient to make treatment decisions, rapid identification of the bacterial or viral cause of diarrhea is critical for optimal patient management, and to ensure no inappropriate or unnecessary treatment is provided.
Healthcare-associated diarrhea, caused by Clostridium difficile, primarily affects patients within the healthcare system who are currently on antibiotics and can have significant implications, including higher associated mortality and healthcare costs.
Conventional diagnostics include culture, ova and parasite exams, and antigen detection tests. These methods, however, are labor-intensive, unpleasant for technologists to perform, have low sensitivity, and can take as long as five to seven days to produce definitive results.
The Verigene® C. difficile Test (CDF) for healthcare-acquired diarrhea with 027 hypervirulent strain differentiation and Verigene® Enteric Pathogens Test (EP) for community-acquired diarrhea with nine bacterial and viral targets require less than five minutes of user hands-on time and deliver comprehensive results directly from a stool sample in less than two hours. As a result, the Verigene System provides earlier optimization for patient treatment and improved laboratory and hospital efficiency.
The Verigene® Clostridium Difficile Test (CDF) is an automated, multiplex test for rapid identification of C. difficile bacteria, including the PCR ribotype 027 hypervirulent strain.
For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.